Search alternatives:
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
ht decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
5 ht » 5 h (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
ht decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
5 ht » 5 h (Expand Search)
-
61
Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor
Published 2022“…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”
-
62
Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor
Published 2022“…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
RhoA gene expression and activity are impacted with increased intracellular 5HT.
Published 2020“…<p><b>A.</b><i>RhoA</i> mRNA expression is significantly upregulated with FLX and 5HTP compared to controls and is significantly decreased in FLX + MDC. …”
-
71
-
72
-
73
-
74
-
75
-
76
-
77
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT<sub>2A</sub> Antagonists for Nonalcoholic Fatty Liver Disease
Published 2020“…Here, structural modifications of pimavanserin (CNS drug), a 5HT<sub>2A</sub> antagonist approved for Parkinson’s disease, led us to synthesize new peripherally acting 5HT<sub>2A</sub> antagonists. …”
-
78
-
79
-
80